Close Menu

ATLANTA (GenomeWeb) – Treatment with a FLT3 inhibitor improved survival among patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 mutation, according to data presented at the American Association for Cancer Research annual meeting here.

"This is a new practice-changing strategy that is something that we have been needing in the field of acute myelogenous leukemia therapy," Louis Weiner, the director of the Georgetown Lombardi Comprehensive Cancer Center, who was not part of the study, said during a press briefing.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.